SCHEMBL3545266

SCHEMBL3545266

CN1CCN(c2ccc3nc(-c4n[nH]c5ccc(Oc6ccccc6)cc45)[nH]c3c2)CC1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 14/20 0.74
FLT1 P17948 4/20 0.74
ABL1 P00519 6/20 0.73
KDR P35968 2/20 0.65
PDGFRA P16234 1/20 0.65
FGFR2 P21802 1/20 0.65
FGFR4 P22455 1/20 0.65
FGFR3 P22607 1/20 0.65
BCR P11274 1/20 0.57
FLT3 P36888 1/20 0.56
KDM4E B2RXH2 1/20 0.55
NPC1 O15118 1/20 0.55
ALDH1A1 P00352 1/20 0.55
POLB P06746 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13548701 0.94 FGFR1 (0.64) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3536287 0.93 ABL1 (0.74) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3540001 0.92 ABL1 (0.75) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3542675 0.92 FGFR1 (0.67) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3542894 0.91 FGFR1 (0.66) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3536499 0.91 FGFR1 (0.71) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3536163 0.89 FGFR1 (0.66) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3541239 0.89 ABL1 (0.76) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3535334 0.89 FGFR1 (0.69) FGFR1FLT1ABL1KDRPDGFRA
SCHEMBL3536818 0.89 FGFR1 (0.65) FGFR1FLT1ABL1KDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.